REFERENCES
1. 2021 Global AIDS Update: Confronting Inequalities [press release]. Joint United Nations Programme on HIV/AIDS 2021, https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update [accessed 13 November 2022].
2. Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the ”HIV Treatment as Prevention” experience in a Canadian setting. PloS one. 2014;9(2):e87872.
3. KOSAids. Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. Infection & chemotherapy. 2021;53(3):592-616.
4. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. Jama.2020;324(16):1651-1669.
5. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet (London, England). 2012;380(9849):1250-1258.
6. Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. The Lancet Infectious diseases. 2011;11(5):363-371.
7. Chang SY, Lin PH, Cheng CL, et al. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.Scientific reports. 2016;6:35779.
8. Jeong W, Jung IY, Choi H, et al. Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea. AIDS research and human retroviruses. 2019;35(2):213-216.
9. KOSAids. The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infection & chemotherapy.2019;51(1):77-88.
10. Kim MH, Song JE, Ahn JY, et al. HIV antiretroviral resistance mutations among antiretroviral treatment-naive and -experienced patients in South Korea. AIDS research and human retroviruses.2013;29(12):1617-1620.
11. Park M, Kee MK, Rhee J, et al. The trend of transmitted drug resistance in newly diagnosed antiretroviral-naive HIV/AIDS patients during 1999-2012 in South Korea. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2016;81:53-57.
12. Jung EJ, Lee SH, Lee S, et al. Short Communication: Trends in Transmitted Drug Resistance in Treatment-Naive HIV Patients in Korea.AIDS research and human retroviruses. 2020;36(11):905-909.
13. Bang JI, Song KH, Kim SH, et al. Prevalence of primary antiretroviral resistance: trends in Korea. AIDS research and human retroviruses. 2008;24(1):83-85.
14. Chung YS, Choi JY, Yoo MS, Seong JH, Choi BS, Kang C. Phylogenetic transmission clusters among newly diagnosed antiretroviral drug-naïve patients with human immunodeficiency virus-1 in Korea: A study from 1999 to 2012. PloS one. 2019;14(6):e0217817.
15. Kim GJ, Yun MR, Koo MJ, Shin BG, Lee JS, Kim SS. Estimating the origin and evolution characteristics for Korean HIV type 1 subtype B using Bayesian phylogenetic analysis. AIDS research and human retroviruses. 2012;28(8):880-884.
16. Lee JE, Lee SO, Lee S, et al. Epidemiological and phylogenetic analysis for non-B subtypes of human immunodeficiency virus type 1 in Busan, Korea. Scientific reports. 2021;11(1):16000.
17. (KDCA). KDCaPA. Annual report on the notified HIV/AIDS in Korea 2020. 2022 https://www.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=1&pblctDtaSn=2645 [accessed 13 November 2022].
18. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.2006;42(11):1608-1618.
19. Cho YK, Kim JE, Foley BT. High Prevalence of Non-B HIV-1 Subtypes in Overseas Sailors and Prostitutes in Korea. AIDS research and human retroviruses. 2018;34(4):347-353.
20. Xiao P, Li J, Fu G, Zhou Y, Huan X, Yang H. Geographic Distribution and Temporal Trends of HIV-1 Subtypes through Heterosexual Transmission in China: A Systematic Review and Meta-Analysis. International journal of environmental research and public health. 2017;14(7).
21. Zuo L, Liu K, Liu H, et al. Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001–2017). EClinicalMedicine. 2020;18:100238.
22. Justice KMo. Status of foreigners staying by population by year (’00~’21) - Ministry of Justice. 2021, https://www.moj.go.kr/moj/2412/subview.do [accessed 13 November 2022].
23. Rhee SY, Kassaye SG, Barrow G, Sundaramurthi JC, Jordan MR, Shafer RW. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. Journal of the International AIDS Society. 2020;23(9):e25611.
24. Schlösser M, Kartashev VV, Mikkola VH, et al. HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. Viruses. 2020;12(4).
25. Tostevin A, White E, Dunn D, et al. Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV medicine. 2017;18(3):204-213.
26. Weng YW, Chen IT, Tsai HC, et al. Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.BMC infectious diseases. 2019;19(1):741.
27. Pearson J, Shannon K, Krüsi A, et al. Barriers to Governmental Income Supports for Sex Workers during COVID-19: Results of a Community-Based Cohort in Metro Vancouver. 2022;11(9):383.
28. Núñez A, Sreeganga SD, Ramaprasad A. Access to Healthcare during COVID-19. International journal of environmental research and public health. 2021;18(6).
29. Yendewa GA, Sahr F, Lakoh S, et al. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. The Journal of antimicrobial chemotherapy.2019;74(7):2024-2029.